Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — Investor Presentation (January 2019)
30 slides from Cocrystal Pharma's investor presentation, Jan 4, 2019
Slide 1: Cocrystal Pharma Corporate Presentation January 2019
C#CRYSTAL Antiviral Therapies Piteaar MA SINC. Corporate Presentation January 2019 NASDAQ: COCP. www.cocrystalpharma.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated timing of our drug development programs, including milestones, anticipated completion or initiat
Slide 3: Corporate Overview
Corporate Overview Clinical Stage Antiviral Company Influenza Proprietary Drug Discovery Platform Hepatitis Norovirus Merck Influenza Collaboration Gastroenteritis
Slide 4: Seasoned Management Team
Seasoned Management Team Gary Wilcox, Ph.D. icos Cialis: Vice Chairman and Chief Executive Officer ‘tadalafil Over 35 years of executive biotech leadership experience and played a key role in the development of Cialis ‘OMA UCLA Sam Lee, Ph.D. President -_ e ® “A Over 20 years of anti-infective drug
Slide 5: 2019: Strong Outlook
2019: Strong Outlook * Growth in focused therapeutic areas * Continue to build an innovative pipeline * Strategic collaborations and partnerships e Recent collaboration with Merck will accelerate influenza drug development program www.cocrystalpharm
Slide 6: Cocrystal/Merck Team Initiate Influenza Collaboration
Cocrystal/Merck Team Initiate Influenza Collaboration e Recently signed a collaboration agreement e Merck will fund: - Research and development - Clinical development - Worldwide commercialization of any products derived from the collaboration ° Cocrystal will receive an upfront payment (undisclosed
Slide 7: Influenza Death Risk On The Rise in US Despite Vaccines
Influenza Death Risk On The Rise in US Despite Vaccines Ou = Te re ting fo 000 Americans a Flu: season ndeaths top 80,000 Fer year, CDC says September 27, 2018 The New York Times This Fla Season Is the a j Worst in Nearly a Decade san 26,2018 CDC: Pediatric flu deaths rise to 171, tying record wing
Slide 8: Great Opportunity in Influenza Antiviral Market
Great Opportunity in Influenza Antiviral Market Seasonal and pandemic infection - 3-5 million cases of severe illness per year - 250,000 — 500,000 deaths worldwide* Approved influenza therapies have major limitation Multiple product routes of delivery, inhalation, oral, and intravenous (IV) Stock pi
Slide 9: Influenza A/B Inhibitor: Cocrystal/Merck Collaboration Program
Influenza A/B Inhibitor: Cocrystal/Merck Collaboration Program Proprietary influenza A and B crystals ° Broad spectrum, potent dual influenza A/B preclinical lead will be developed - Results of Cocrystal’s drug discovery platform technology - Binds to highly conserved site of influenza A and B repli
Slide 10: Influenza A PB2 Preclinical Lead, CC-42344 Properties
Influenza A PB2 Preclinical Lead, CC-42344 Properties ° Binds to the highly conserved m7GTP binding pocket of PB2 ° Exhibits broad spectrum activity against seasonal and pandemic influenza strains, EC,, 0.12-9 nM * Favorable preclinical safety profile and pharmacokinetic properties ° Multiple routes
Slide 11: Cocrystal Technology
Cocrystal Technology Based on Nobel Prize Winning Technology Lo | Near atomic resolution, ® X-ray quality crystal production @ Drug pocket selection @ Hit-to-lead process @ Lead optimization e Drug candidates www.cocrystalpharma.com
Slide 12: Innovative Drug Discovery Platform Technology Developed
Innovative Drug Discovery Platform Technology Developed Protein Engineering Expression & Purification crystal production ighput X-ray lography diffraction ome aa Ge screening Fully optimized operations from expression through high resolution X-ray data Stringent Quality oversight of procedures for c
Slide 13: Cocrystal Technology Platform
Cocrystal Technology Platform — Proven track record for broad spectrum antiviral leads Cc-31244 CC-31647 Fresipical Cocrystal platform > technology focuses on: e Lead Discovery ° Well validated drug targets ( Cocrystal Merck/Cocrystal) * Broad spectrum activity Structures ° Drug resistance CC-42344
Slide 14: Robust Development Pipeline
Robust Development Pipeline Phasel Phase2a Phase2b = Phase3 artner 8 5 2 = 8 Program cc-31244- University of MD (Pan-genotypic NSSB Hepatitis C | NNI) (Hev) (CC-31244 - Hong Kong (Pan-genotypic NSSB ‘NNI) cc-42344 (influenza A PB2 inhibitor) Influenza Influenza A/B inhibitor Noro Polymerase Noroviru
Slide 15: Cocrystal's HCV Strategy: Shorter Duration Novel Combination Therapy
Cocrystal’s HCV Strategy: Shorter Duration Novel Combination Therapy Multiple opportunities in developing shorter combination therapy with approved HCV drugs Gilead EPCLUSA + CC-31244 AbbVie Mavyret + CC-31244 Other approved HCV drugs + CC-31244 www.cocrystalpharma.com
Slide 16: Cocrystal's Next Wave Combination Therapy: CC-31244 Properties
Cocrystal’s Next Wave Combination Therapy: CC-31244 Properties * Potential best-in-class HCV NNI with a strong profile Broad spectrum, potent NS5B polymerase inhibitor High barrier to drug resistance Effective against known NNI drug resistant variants Liver targeting Novel mechanism of action
Slide 17: CC-31244: Broad Spectrum HCV NNI
CC-31244: Broad Spectrum HCV NNI Demonstration of Cocrystal’s Enabling Technology HCV GT1 — GT6 NS5B polymerase crystals CC-31244 HCV NSS5B polymerase Proven track record for broad spectrum antiviral leads www.cocrystalphi
Slide 18: Hepatitis C Treatment Market Share
Hepatitis C Treatment Market Share 2017 Annual Sales: $12.69 Billion Nine Months 2018 Sales: $6.3 Billion Gilead $9.14 B Gilead (Harvoni, Epclusa, Sovaldi, Vosevi) mJ&J (Olysio) mAbbVie (Viekira, Mavyret) _ ™ Merck (Zepatier) Source: 2017 Form 10-K Source: 2018 Form 10-Q. www.cocrystalpharma.com
Slide 19: AbbVie's Mavyret Demonstrated a Shorter Treatment
AbbVie’s Mavyret Demonstrated a Shorter Treatment: From 12 Weeks To 8 Weeks Approved broad spectrum HCV combination therapy Nucleoside/NS5A inhibitors Protease/NSSA inhibitors Gilead’s EPCLUSA AbbVie’s Mavyret (sofosbuvir 400mg/ (glecaprevir 100 mg/ velpatasvir 100 mg) pibrentasvir 40 mg) 12-week tr
Slide 20: CC-31244 Phase 1b Data - Superior Viral Load Reduction
CC-31244 Phase 1b Data - Superior Viral Load Reduction * HCV RNA viral load decline of 3 logs by 48 hours (HCV GT1 subjects, N=14) ° After the NNI treatment, the viral load levels slowly increased Mean Viral Load Change From Baseline (CC-31244 at 400 mg QD or 200 mg BID x 7 days) i CC-31244 No CC-31
Slide 21: Best-in-Class Potential of Any NNI
Best-in-Class Potential of Any NNI Dose Treatment Vural load Drug Genotype (mg) Geminis reduction 2 shay (Log,olU/ml) CC-31244 @ Genotypes1-6 ¢= 400 QD « 3.0 = ABT-333* (Dasabuvir) Genotype 1 400 BID -1.08 800 BID -0.95 GS-9190 (Tegobuvir) Genotype 1 40 BID -1.0 120 BID a5 (* : approved DAA) C#CRYST
Slide 22: CC-31244 Phase 2a Study Design
CC-31244 Phase 2a Study Design Interim Topline Results Expected January 2019 Open-label, Phase 2a study evaluating the safety, tolerability and preliminary efficacy of CC-31244 with approved HCV DAAs €C-31244 (400 mg) QD so sofosbuvir and Follow up at velpatasvir 12 & 24 weeks sofosbuvir and Aweeks
Slide 23: Upcoming CC-31244 Phase 2a Study in Hong Kong
Upcoming CC-31244 Phase 2a Study in Hong Kong Sponsored and Conducted by the Humanity & Health Research Centre (Principle Investigator: Dr. George Lau) Open-label, safety, tolerability and preliminary efficacy of CC-31244 in combination with Sofosbuvir and Daclatasvir with or without a protease inhi
Slide 24: HCV Summary and Next Steps
HCV Summary and Next Steps * Showed an acceptable safety profile in both healthy volunteers and GT1 patients up to 400 mg x 7 days * No serious adverse events or discontinuations due to adverse events * Demonstrated HCV RNA viral load reduction of ~ 3 logs by 48 hours * Demonstrated a sustained post
Slide 25: Noro Virus Polymerase Inhibitor
Noro Virus Polymerase Inhibitor Noro virus and Norwalk polymerase crystals * No approved Noro antiviral drugs Potent and broad spectrum anti-Noro polymerase inhibitors First-in-class NNI Structure-based lead discovery ongoing
Slide 26: Cocrystal-HitGen-InterX Collaboration
Cocrystal-HitGen-InterX Collaboration: Aimed at Rapid Lead Discovery Process * Combines synergistic drug discovery platforms ai ° Breakthrough hit-to-lead process ¢ High quality novel leads will be developed www.cocrystalphi
Slide 27: Financial Snapshot
Financial Snapshot — Nasdaq: COCP ~$108MM 29.9MM ~42K Market cap" Common shares Average daily outstanding volume? Based on December 31, 2018 closing price of $3.60 per share Based on December 31, 2018 Yahoo Finance
Slide 28: COCP Capitalization Table
COCP Capitalization Table Capitalization Table (As of December 31, 2018) # of Shares WAEP $ Value re Common Shares Outstanding (Directors & Officers) 15,219,800 48.37% Common Shares Outstanding (Other) 14,703,276 46.73% Warrants 243,375, $10.28 $2,501,895 0.77% Stock Options 1,297,953 $5.77 $7,483,6
Slide 29: Near-Term Milestones Expected to Drive Value
Near-Term Milestones Expected to Drive Value * Continue influenza A/B lead discovery (Merck collaboration) * Continue preclinical studies of influenza A lead CC-42344 * Complete HCV CC-31244 Phase 2a (University of Maryland, Baltimore) * Commence HCV CC-31244 Phase 2a (Humanity & Health Research Cen
Slide 30: Thank You!
C¥CRYSTAL PHARMA,INC Thank You! NASDAQ: COCP. www.cocrystalpharma.com
Cocrystal Pharma — Investor Presentation (January 2019) on 6ix